Oncology PracticePeptide vaccine shows early promise in ovarian, endometrial cancersMarch 25, 2017Gynecologic CancerImmunotherapy
Oncology PracticeConnective tissue diseases reported in patients receiving immune checkpoint inhibitorsMarch 3, 2017Patient & Survivor CareImmunotherapyAggressive LymphomasMelanomaImmuno-oncology
Oncology PracticeNivolumab shows promise for pretreated advanced HCCFebruary 3, 2017GastroenterologyImmunotherapyGI OncologyGastrointestinal Cancer
Oncology PracticeNivolumab effective in PD-L1–deficient lung cancersJanuary 24, 2017Lung CancerImmunotherapy
Oncology PracticeNivolumab safe, effective for salvage in advanced gastric cancerJanuary 21, 2017GastroenterologyImmunotherapyRare DiseasesGastrointestinal Cancer
Oncology PracticeVIDEO: Improved QOL an added benefit of pembrolizumab for NSCLC patientsDecember 14, 2016Lung CancerPatient & Survivor CareImmunotherapy
Oncology PracticeOncolytic virus active against bladder cancerNovember 30, 2016Genitourinary CancerImmunotherapy
Oncology PracticeVaccine/PD-1 inhibitor combo shows early promise against mCRPCNovember 29, 2016Genitourinary CancerImmunotherapy
The Journal of Community and Supportive OncologySplit-dose R-CHOP: a new approach to administer cytotoxic chemo-immunotherapy to elderly patients with DLBCLNovember 22, 2016Lymphoma & Plasma Cell DisordersImmunotherapy
The Journal of Community and Supportive OncologyLessons learned from using CDK 4/6 inhibitors to treat metastatic breast cancerNovember 3, 2016Breast CancerPatient & Survivor CareImmunotherapy
The Journal of Community and Supportive OncologySlow and steady progress in managing gynecologic cancer August 24, 2016Gynecologic CancerImmunotherapy
The Journal of Community and Supportive OncologyEvolving therapeutic strategies maintain clinical momentum in melanomaJune 29, 2016MelanomaImmunotherapy
The Journal of Community and Supportive OncologyMore success for immunotherapy with nivolumab approval for metastatic RCCApril 27, 2016Genitourinary CancerImmunotherapy
The Journal of Community and Supportive OncologyEncouraging data on immunotherapy, cardiotoxicity, and DFSFebruary 21, 2016Breast CancerImmunotherapy
The Journal of Community and Supportive OncologyMaking immunotherapy part of routine breast cancer treatmentFebruary 21, 2016Breast CancerPatient & Survivor CareImmunotherapy
